title: Disease due to Mycobacterium kansasii in the Czech Republic: 1984-89.
abstract: METHODS
  Endemic area of North Moravia, Czech Republic.
  
  
  OBJECTIVE
  Evaluate the incidence of human disease due to Mycobacterium kansasii. The follow-up of some bacteriological and clinical features.
  
  
  METHODS
  A retrospective analysis of M. kansasii patients.
  
  
  RESULTS
  M. kansasii was isolated from the sputum, tissue and other specimens obtained from 650 persons during the period 1984-89. In only 471 of them was this mycobacterium deemed to be the causative agent, predominantly of lung disease. The most typical radiographic finding in these patients was lung infiltration and/or thin-walled cavity.
  
  
  CONCLUSIONS
  As in previous years the highest incidence of disease remains in an endemic area of North Moravia. The effects of treatment in follow-up patients were influenced not only by the antituberculosis regimen but also by a high frequency of associated diseases. Sputum conversion within 30 days was not affected by the presence or absence of a cavity. Authors consider water to be the source of infection.
authors.affiliation: National Reference Laboratory for M. kansasii of the Czech Republic, Regional Institute of Hygiene, Ostrava, Czech Republic.
authors.forename: J
authors.initials: J
authors.lastname: Kaustová
authors.forename: M
authors.initials: M
authors.lastname: Chmelík
authors.forename: D
authors.initials: D
authors.lastname: Ettlová
authors.forename: V
authors.initials: V
authors.lastname: Hudec
authors.forename: H
authors.initials: H
authors.lastname: Lazarová
authors.forename: S
authors.initials: S
authors.lastname: Richtrová
mesh_terms: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents / Q000627:therapeutic use; D018153:Czech Republic / Q000453:epidemiology; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000150:complications / Q000453:epidemiology* / Q000382:microbiology; D009170:Nontuberculous Mycobacteria / Q000302:isolation & purification*; D012189:Retrospective Studies; D012293:Rifampin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000150:complications
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D012293:Rifampin